117 related articles for article (PubMed ID: 23235339)
21. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
22. WT1 Clone 6F-H2 Cytoplasmic Expression Differentiates Astrocytic Tumors from Astrogliosis and Associates with Tumor Grade, Histopathology, IDH1 Status, Apoptotic and Proliferative Indices: A Tissue Microarray Study.
Abd El-Hafez A; Ismail Hany HSED
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2403-2413. PubMed ID: 32856872
[TBL] [Abstract][Full Text] [Related]
23. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma.
Avliyakulov NK; Rajavel KS; Le KM; Guo L; Mirsadraei L; Yong WH; Liau LM; Li S; Lai A; Nghiemphu PL; Cloughesy TF; Linetsky M; Haykinson MJ; Pope WB
J Neurooncol; 2014 Mar; 117(1):53-65. PubMed ID: 24473683
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.
Malueka RG; Theresia E; Fitria F; Argo IW; Donurizki AD; Shaleh S; Innayah MR; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA; Dwianingsih EK
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3229-3234. PubMed ID: 33247679
[TBL] [Abstract][Full Text] [Related]
25. A sensitive and specific diagnostic panel to distinguish diffuse astrocytoma from astrocytosis: chromosome 7 gain with mutant isocitrate dehydrogenase 1 and p53.
Camelo-Piragua S; Jansen M; Ganguly A; Kim JC; Cosper AK; Dias-Santagata D; Nutt CL; Iafrate AJ; Louis DN
J Neuropathol Exp Neurol; 2011 Feb; 70(2):110-5. PubMed ID: 21343879
[TBL] [Abstract][Full Text] [Related]
26. Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report.
Søndergaard CB; Scheie D; Sehested AM; Skjøth-Rasmussen J
Childs Nerv Syst; 2017 Jul; 33(7):1217-1220. PubMed ID: 28236063
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
[TBL] [Abstract][Full Text] [Related]
28. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome.
Watanabe T; Vital A; Nobusawa S; Kleihues P; Ohgaki H
Acta Neuropathol; 2009 Jun; 117(6):653-6. PubMed ID: 19340432
[TBL] [Abstract][Full Text] [Related]
29. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
[TBL] [Abstract][Full Text] [Related]
30. Microfluidics for rapid detection of isocitrate dehydrogenase 1 mutation for intraoperative application.
Aibaidula A; Zhao W; Wu JS; Chen H; Shi ZF; Zheng LL; Mao Y; Zhou LF; Sui GD
J Neurosurg; 2016 Jun; 124(6):1611-8. PubMed ID: 26544771
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers.
Kang MR; Kim MS; Oh JE; Kim YR; Song SY; Seo SI; Lee JY; Yoo NJ; Lee SH
Int J Cancer; 2009 Jul; 125(2):353-5. PubMed ID: 19378339
[TBL] [Abstract][Full Text] [Related]
32. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.
Loussouarn D; Le Loupp AG; Frenel JS; Leclair F; Von Deimling A; Aumont M; Martin S; Campone M; Denis MG
Int J Oncol; 2012 Jun; 40(6):2058-62. PubMed ID: 22447191
[TBL] [Abstract][Full Text] [Related]
33. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Capper D; Reuss D; Schittenhelm J; Hartmann C; Bremer J; Sahm F; Harter PN; Jeibmann A; von Deimling A
Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing.
Kim BYS; Jiang W; Beiko J; Prabhu SS; DeMonte F; Gilbert MR; Sawaya R; Aldape KD; Cahill DP; McCutcheon IE
J Neurooncol; 2014 Jun; 118(2):405-412. PubMed ID: 24777756
[TBL] [Abstract][Full Text] [Related]
35. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
[TBL] [Abstract][Full Text] [Related]
36. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
37. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
38. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
Motomura K; Mittelbronn M; Paulus W; Brokinkel B; Keyvani K; Sure U; Wrede K; Nakazato Y; Tanaka Y; Pierscianek D; Kim YH; Mariani L; Vital A; Ohgaki H
J Neuropathol Exp Neurol; 2012 Aug; 71(8):702-7. PubMed ID: 22805772
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of IDH1 status in diffusely infiltrating gliomas by immunohistochemistry using anti-mutant and wild type IDH1 antibodies.
Ikota H; Nobusawa S; Arai H; Kato Y; Ishizawa K; Hirose T; Yokoo H
Brain Tumor Pathol; 2015 Oct; 32(4):237-44. PubMed ID: 26006098
[TBL] [Abstract][Full Text] [Related]
40. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
